BRPI0413889A - formulação lipossÈmica farmacêutica - Google Patents

formulação lipossÈmica farmacêutica

Info

Publication number
BRPI0413889A
BRPI0413889A BRPI0413889-9A BRPI0413889A BRPI0413889A BR PI0413889 A BRPI0413889 A BR PI0413889A BR PI0413889 A BRPI0413889 A BR PI0413889A BR PI0413889 A BRPI0413889 A BR PI0413889A
Authority
BR
Brazil
Prior art keywords
formulation
photosensitizer
polar
phospholipids
liposomal
Prior art date
Application number
BRPI0413889-9A
Other languages
English (en)
Inventor
Volker Albrecht
Alfred Fahr
Dietrich Scheglmann
Susanna Grafe
Original Assignee
Ceramoptec Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceramoptec Ind Inc filed Critical Ceramoptec Ind Inc
Publication of BRPI0413889A publication Critical patent/BRPI0413889A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçãO LIPOSSÈMICA FARMACêUTICA". é descrita uma formulação lipossómica farmacêutica, para terapia fotodinâmica, compreendendo um fotossensibilizante de porfirina não polar e um ou mais fosfolipídios, que são estáveis na armazenagem sem exigir congelamento-secagem. A formulação lipossómica proporciona quantidades terapeuticamente efetivas do fotossensibilizante para administração intravenosa. Os fosfolipídios podem ser modificados por peguilação, isto é, contêm polietilenoglicol como parte integral dos fosfolipídios. Os lipossomas formados contêm o fotossensibilizante não polar dentro da membrana e são úteis para o alvejamento combinado de um fotossensibilizante não polar e uma segunda substância polar. Quando uma formulação incluir a presença de monossacarídeos ou poliálcoois, pode ser eficazmente congelada-seca, preservando o tamanho dos veículos lipossómicos e o conteúdo de uma quantidade terapêuticamente efetiva do agente fotossensibilizante. A invenção também se relaciona com a composição lipossómica formada por reconstituição com um veículo aquoso. A formulação congelada-seca por reconstituição com um veículo aquoso apropriado forma lipossomas que são também úteis para administração intravenosa.
BRPI0413889-9A 2003-08-26 2004-06-23 formulação lipossÈmica farmacêutica BRPI0413889A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/648,168 US20050048109A1 (en) 2003-08-26 2003-08-26 Non-polar photosensitizer formulations for photodynamic therapy
PCT/US2004/020163 WO2005023220A1 (en) 2003-08-26 2004-06-23 Non-polar photosensitizer formulations for photodynamic therapy

Publications (1)

Publication Number Publication Date
BRPI0413889A true BRPI0413889A (pt) 2006-10-24

Family

ID=34216686

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413889-9A BRPI0413889A (pt) 2003-08-26 2004-06-23 formulação lipossÈmica farmacêutica

Country Status (16)

Country Link
US (3) US20050048109A1 (pt)
EP (2) EP2471512B1 (pt)
JP (2) JP4869929B2 (pt)
KR (3) KR100975160B1 (pt)
CN (1) CN1842322B (pt)
AU (1) AU2004270119B2 (pt)
BR (1) BRPI0413889A (pt)
CA (2) CA2746516C (pt)
DK (2) DK2471512T3 (pt)
ES (2) ES2566681T3 (pt)
HU (1) HUE026790T2 (pt)
IL (2) IL173808A (pt)
PL (2) PL1660041T3 (pt)
PT (1) PT1660041E (pt)
RU (1) RU2343904C2 (pt)
WO (1) WO2005023220A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
US8986731B2 (en) * 2003-08-26 2015-03-24 Biolitec Pharma Marketing Ltd Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US20080103213A1 (en) * 2004-03-05 2008-05-01 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of neurofibromatosis
US20090297592A1 (en) * 2005-05-11 2009-12-03 Jcr Pharmaceuticals Co., Ltd. Lipid Vesicle Composition
US20070031482A1 (en) * 2005-08-02 2007-02-08 Ceramoptec Industries, Ind. PDT treatment method for cellulites and cosmetic use
US8999933B2 (en) * 2006-01-18 2015-04-07 Biolitec Pharma Marketing Ltd Photodynamic cosmetic procedure and healing method
TW200738278A (en) * 2006-04-03 2007-10-16 Univ Taipei Medical A liposome combination and the use thereof
US20090081281A1 (en) * 2006-05-10 2009-03-26 Gerard Farmer Photosensitizer Formulation for Topical Applications
US20080275432A1 (en) * 2006-05-11 2008-11-06 Ceramoptec Industries, Inc. Photodynamic foam composition and sclerosis treatment
EP2034963B1 (en) * 2006-05-18 2022-08-10 biolitec Unternehmensbeteiligungs II AG Gel-formulations of hydrophobic photosensitizers for mucosal applications
CZ2006743A3 (cs) * 2006-11-28 2008-03-26 Fyziologický ústav AV CR Liposomální gelový ftalocyaninový prípravek pro fotodynamickou terapii nádorových onemocnení a zpusob jeho prípravy
US20090162423A1 (en) * 2007-12-20 2009-06-25 Ceramoptec Industries, Inc. Formulations for cosmetic and wound care treatments with photosensitizes as fluorescent markers
WO2008088037A1 (ja) * 2007-01-18 2008-07-24 National University Corporation Chiba University 微粒子製剤
US20080214460A1 (en) * 2007-01-18 2008-09-04 Ceramoptec Industries, Inc. Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
WO2009067217A1 (en) * 2007-11-20 2009-05-28 Ceramoptec Industries, Inc. Pdt assisted scar prevention and vision correction
ES2707228T3 (es) 2008-09-18 2019-04-03 Biolitec Unternehmensbeteiligungs Ii Ag Nuevo método y aplicación de porfirinas y clorinas asimétricamente meso-sustituidas para TFD
US8815931B2 (en) * 2009-04-28 2014-08-26 Biolitec Pharma Marketing Ltd Oral formulations for tetrapyrrole derivatives
US20110275686A1 (en) * 2009-12-11 2011-11-10 Biolitec, Inc. Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)
RU2428981C1 (ru) * 2010-03-31 2011-09-20 Анатолий Юрьевич Барышников Средство для фотодинамической терапии, способ получения предлагаемого средства и способ проведения фотодинамической терапии с использованием предлагаемого средства
RU2446842C2 (ru) * 2010-07-15 2012-04-10 Учреждение Российской академии наук Центральная клиническая больница РАН Способ лечения местнораспространенных онкологических заболеваний в эксперименте
CN102432755B (zh) * 2011-09-05 2013-11-13 苏州大学 多重靶向性的光动力学疗法聚合物载体及其制备方法
US10117942B2 (en) 2013-07-12 2018-11-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photoactivatable lipid-based nanoparticles as vehicles for dual agent delivery
US10456375B2 (en) 2014-09-30 2019-10-29 Biolitec Unternehmensbeteiligungs Ii Ag Specifically meso-substituted porphyrins and chlorins for photodynamic therapy
JP5995207B2 (ja) * 2014-11-28 2016-09-21 学校法人 学習院 含ホウ素ポルフィリン誘導体
CN105311632A (zh) * 2015-10-27 2016-02-10 浙江大学 负载光动力治疗药物的细胞膜微囊的制备方法
ES3011714T3 (en) 2016-02-26 2025-04-08 Biolitec Holding Gmbh & Co Kg Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy
CZ307681B6 (cs) 2016-02-29 2019-02-13 Ústav makromolekulární chemie AV ČR, v. v. i. Fotoaktivovatelná nanočástice pro fotodynamické aplikace, způsob její přípravy, farmaceutická kompozice ji obsahující a jejich použití
CN106421810B (zh) * 2016-09-26 2019-08-20 武汉大学 一种肿瘤靶向细胞药物载体及其应用
US12178907B2 (en) 2018-07-12 2024-12-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Binary lipid bilayer-containing vesicles comprising embedded cytotoxic agents and methods of making and using the same
EP3894421A1 (en) 2018-12-10 2021-10-20 Universität Hamburg Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy
KR102203483B1 (ko) * 2018-12-28 2021-01-14 서울대학교산학협력단 방사성 금속 및 유로피움을 포함하는 광역동 요법용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB214525A (en) * 1923-09-13 1924-04-24 Ella Martin Improvements in terminals for electric cables
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
IL69720A (en) * 1983-09-14 1987-08-31 Univ Ramot Anti-tumor pharmaceutical compositions comprising liposome-bound porphyrins
US5190761A (en) * 1986-08-05 1993-03-02 Liburdy Robert P Electromagnetic field triggered drug and chemical delivery via liposomes
US5162519A (en) * 1988-03-11 1992-11-10 Efamol Holdings Plc Porphyrins and cancer treatment
GB8805849D0 (en) * 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
JP3037994B2 (ja) * 1989-11-02 2000-05-08 テルモ株式会社 リポソーム表面への蛋白質吸着抑制剤
CA2047969A1 (en) * 1990-08-17 1992-02-18 Thomas D. Madden Benzoporphyrin vesicles
CA2087902C (en) * 1992-02-05 2006-10-17 Narendra Raghunathji Desai Liposome compositions of porphyrin photosensitizers
US6890555B1 (en) * 1992-02-05 2005-05-10 Qlt, Inc. Liposome compositions of porphyrin photosensitizers
EP0784470B1 (en) * 1994-10-03 2003-08-13 INFECTIO RECHERCHE Inc. Liposome-formulations for treatment of viral diseases
US6974666B1 (en) * 1994-10-21 2005-12-13 Appymetric, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US5935942A (en) * 1994-12-14 1999-08-10 Zeimer; Ran Selective and non-invasive visualization or treatment of vasculature
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US5707608A (en) * 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6043237A (en) * 1996-12-10 2000-03-28 Qlt Phototherapeutics, Inc. Use of photodynamic therapy for prevention of secondary cataracts
NZ337693A (en) * 1997-03-10 2001-07-27 Res Dev Foundation Photodynamic therapy generated oxidative stress for temporal and selective expression of heterologous genes
US6010890A (en) * 1997-04-29 2000-01-04 New York Blood Center, Inc. Method for viral inactivation and compositions for use in same
GB9710049D0 (en) * 1997-05-19 1997-07-09 Nycomed Imaging As Method
JP4444385B2 (ja) * 1999-02-25 2010-03-31 帝人株式会社 リポソーム用時調製用キット
EP1206288B1 (en) * 1999-08-02 2007-01-10 The Regents Of The University Of Michigan Targeted fiberless radiative effectors
DE60123583T2 (de) * 2000-02-04 2007-08-09 Lipoxen Technologies Ltd. Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
GB0005855D0 (en) * 2000-03-10 2000-05-03 Scotia Holdings Plc Compounds for pdt
AU2001258117A1 (en) * 2000-05-08 2001-11-20 The University Of British Columbia Supports for photosensitizer formulations
JP2001348341A (ja) * 2000-06-06 2001-12-18 Terumo Corp 低酸素状態の細胞および組織に有効な人工酸素運搬体
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy

Also Published As

Publication number Publication date
KR20080027974A (ko) 2008-03-28
ES2403601T3 (es) 2013-05-20
US20060088584A1 (en) 2006-04-27
CA2746516A1 (en) 2005-03-17
EP1660041A4 (en) 2010-01-27
WO2005023220A1 (en) 2005-03-17
US7354599B2 (en) 2008-04-08
KR20080110685A (ko) 2008-12-18
JP2007503436A (ja) 2007-02-22
IL173808A0 (en) 2006-07-05
RU2343904C2 (ru) 2009-01-20
KR100975160B1 (ko) 2010-08-10
PT1660041E (pt) 2013-05-15
AU2004270119B2 (en) 2008-06-05
JP4869929B2 (ja) 2012-02-08
HUE026790T2 (en) 2016-07-28
IL173808A (en) 2015-11-30
KR20060039451A (ko) 2006-05-08
IL203995A (en) 2017-05-29
KR100973064B1 (ko) 2010-08-17
US20060159740A1 (en) 2006-07-20
JP5639014B2 (ja) 2014-12-10
AU2004270119A1 (en) 2005-03-17
KR100887785B1 (ko) 2009-03-09
PL2471512T3 (pl) 2016-08-31
EP1660041A1 (en) 2006-05-31
RU2006109497A (ru) 2007-10-10
CN1842322A (zh) 2006-10-04
JP2011213731A (ja) 2011-10-27
PL1660041T3 (pl) 2013-08-30
DK1660041T3 (da) 2013-06-03
CA2536977C (en) 2011-10-11
EP1660041B1 (en) 2013-03-06
US20050048109A1 (en) 2005-03-03
CA2746516C (en) 2013-05-07
DK2471512T3 (en) 2016-04-04
CA2536977A1 (en) 2005-03-17
EP2471512B1 (en) 2016-03-16
CN1842322B (zh) 2011-05-04
EP2471512A2 (en) 2012-07-04
ES2566681T3 (es) 2016-04-14
EP2471512A3 (en) 2012-07-11

Similar Documents

Publication Publication Date Title
BRPI0413889A (pt) formulação lipossÈmica farmacêutica
Aroso et al. Photodynamic disinfection and its role in controlling infectious diseases
US9480707B2 (en) Methods and systems for treatment of inflammatory diseases with nitric oxide
US9937202B2 (en) Topical nitric oxide systems and methods of use thereof
Kyle et al. Topical therapy for fungal infections
CN101594885B (zh) 利福昔明抗直肠功能障碍制剂
US8062663B2 (en) Methods and compostions for enhancing transdermal drug delivery
Van Hoogevest et al. The use of phospholipids to make pharmaceutical form line extensions
ES2908689T3 (es) Composición formadora de capa lipídica para administración sobre la superficie de un organismo vivo
BRPI0411982A (pt) glicano de aperfeiçoamento de terapia
BR0211613A (pt) Composições farmacêuticas contendo beta-lapachone ou derivados ou análogos seus, e processos de emprego das mesmas
CA1238275A (en) Menthol enhancement of transdermal drug delivery
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
EP0221176A1 (en) PHARMACEUTICAL CARRIERS FOR REDUCING THE TRANSDERMAL FLOW.
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
ES2315541T3 (es) Formulaciones que contienen melatonina, ginkgo biloba y biotina.
BR0117197A (pt) Formulação de medicamento contendo ciclosporina aplicação do mesmo
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
CN110709061A (zh) 抗沉淀的小分子药物制剂
CN102284059A (zh) 一种光敏剂及其制备方法和应用
CN102283850B (zh) 一种水包油型复方酮康唑纳米药物及其制备方法
JP2016513686A (ja) フルチカゾンの経皮製剤
JP2000038352A (ja) 外用組成物
ES2673627T3 (es) Liposomas que contienen ácido di-homo-gamma linolénico (DGLA), formulaciones que los contienen y uso de los mismos
US4873266A (en) Menthone enhancement of transdermal drug delivery

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: BIOLITEC PHARMA MARKETING LTD. (MY)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time